Eli Lilly enters $1.6B cancer research partnerships with Merus

Listen
Text
  • Small
  • Medium
  • Large

Loxo Oncology, Eli Lilly's cancer-specific biotech unit, partnered with Dutch cancer drugmaker Merus Jan. 19 to develop three cancer antibody therapies in a deal amounting to $1.6 billion.

Eli Lilly will pay Merus $40 million up front in cash, as well as buy $20 million in Merus common shares as an equity investment. Under the deal, Merus is also eligible to receive up to $540 million in development and commercialization milestones per product, which could total up to $1.6 billion for the three antibody therapies.

The antibody therapies will be developed out of Merus’ Biclonics platform, which creates antibody therapies that engage CD3 cells and redirect T-cells.

"CD3-engaging bispecific antibodies are rapidly becoming one of the most transformative immune-modulating modalities used to treat cancer," Loxo Oncology COO Jacob Van Naarden said in a news release. "We expect these therapies will become an important component of the Loxo Oncology at Lilly biologics strategy."

More articles on pharmacy:
Former NJ pharmacy owner admits to role in multimillion dollar kickback scheme
Mercy to operate 22 supermarket pharmacies in St. Louis area
Pfizer vaccine protects against UK coronavirus variant, study shows

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars